<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01077427</url>
  </required_header>
  <id_info>
    <org_study_id>115-09</org_study_id>
    <secondary_id>2008-004802-14</secondary_id>
    <secondary_id>AIO-PAK-0111</secondary_id>
    <nct_id>NCT01077427</nct_id>
  </id_info>
  <brief_title>Hyperthermia European Adjuvant Trial</brief_title>
  <acronym>HEAT</acronym>
  <official_title>A Randomized Two-armed Open Study on the Adjuvant Therapy in Patients With R0/R1 Resected Pancreatic Carcinoma With Gemcitabine Plus Capecitabine (Arm GC) vs. Gemcitabine Plus Cisplatin With Regional Hyperthermia (Arm GPH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Klinikum der Universitaet Muenchen, Grosshadern</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The European Society for Hyperthermic Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Klinikum der Universitaet Muenchen, Grosshadern</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Improvement of the clinical outcome in patients with resectable pancreatic carcinoma through&#xD;
      an intensified adjuvant treatment with gemcitabine, cisplatin and regional deep hyperthermia&#xD;
      as compared to standard chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From date of randomization until the date of death from any cause assessed up to 60 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Toxicity</measure>
    <time_frame>Permanent assessment</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Permanent assessment</time_frame>
    <description>EORTC QLQ C30</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">336</enrollment>
  <condition>Resected Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Gemcitabine + Capecitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcitabine + Cisplatin + regional hyperthermia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Gemcitabine + Cisplatin + regional hyperthermia</intervention_name>
    <description>Gemcitabine: 1000 mg/m² as iv-infusion on days 1 and 15 of each course (Total dose: 12 g/m²)&#xD;
Cisplatin: 25 mg/m² as iv-infusion on days 2, 3* and 16, 17* of each course (Total dose: 600 mg/m²)&#xD;
Regional hyperthermia: 60 minutes on days 2, 3*, and 16, 17* of each course&#xD;
* as an exception for medical or logistic reasons RHT and cisplatin can be applied day 4 instead of 3 and day 18 instead of 17</description>
    <arm_group_label>Gemcitabine + Cisplatin + regional hyperthermia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine + Capecitabine</intervention_name>
    <description>Gemcitabine: 1000 mg/m² as iv-infusion on days 1, 8 and 15 of each course (Total dose: 18 g/m²)&#xD;
Capecitabine: daily dose of 1660 mg/m²; administered orally for 21 days followed by 7 days' rest (one cycle) for six cycles</description>
    <arm_group_label>Gemcitabine + Capecitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Any ductal adenocarcinoma of the pancreas confirmed by histology&#xD;
&#xD;
          2. Previous R0 or R1 resection of pancreatic tumor with a standardized procedure&#xD;
&#xD;
          3. No other previous or concomitant treatment of pancreatic carcinoma like radiation,&#xD;
             neoadjuvant therapy or immunotherapy&#xD;
&#xD;
          4. No tumor recurrence after surgery&#xD;
&#xD;
          5. Performance status ECOG 0-2&#xD;
&#xD;
          6. Adequate bone marrow function defined as&#xD;
&#xD;
               -  WBC count ≥ 3.5 x 109/L and&#xD;
&#xD;
               -  platelets ≥ 150 x 109/L and&#xD;
&#xD;
               -  haemoglobin ≥ 9 g/dl documented within 1 week prior to randomization&#xD;
&#xD;
          7. Adequate renal function defined as&#xD;
&#xD;
               -  serum creatinine ≤ 1.2 mg/dL and&#xD;
&#xD;
               -  calculated GFR ≥ 60 mL/min documented within 1 week prior to randomization&#xD;
&#xD;
          8. Adequate coagulatory function defined as&#xD;
&#xD;
               -  Quick-value ≥ 70% and&#xD;
&#xD;
               -  aPTT ≤ 1.5 x ULN documented within 1 week prior to randomization&#xD;
&#xD;
          9. Transaminases (AST, ALT) ≤ 3 x ULN and bilirubin ≤ 2 x ULN documented within 1 week&#xD;
             prior to randomization&#xD;
&#xD;
         10. At least 18 years of age&#xD;
&#xD;
         11. Women with childbearing potential and fertile men must use adequate contraceptive&#xD;
             measures during and for at least 3 months (female) and 6 months (male) after&#xD;
             completion of study therapy (Adequate methods for women are oral contraceptives with&#xD;
             estrogen and progesterone, vaginal rings, contraceptive patches, estrogen-free&#xD;
             ovulation inhibitors, intrauterine devices with progesterone, 3-month injections with&#xD;
             depot progesterone, implants setting free progesterone, abstinence or sterilization&#xD;
             (vasectomy) of the male partner. Men must use condoms.)&#xD;
&#xD;
         12. Women with childbearing potential must have a negative pregnancy test within 1 week&#xD;
             prior to randomization (postmenopausal women with amenorrhea for more than 1 year are&#xD;
             regarded as having no childbearing potential)&#xD;
&#xD;
         13. Written informed consent&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Cystic carcinoma of the pancreas&#xD;
&#xD;
          2. Periampullary, papillary cancer&#xD;
&#xD;
          3. Metastatic disease&#xD;
&#xD;
          4. Presence of an active infection grade 3 or higher&#xD;
&#xD;
          5. Other severe disease which could impair the patient's ability to participate in the&#xD;
             study according to the investigator's opinion&#xD;
&#xD;
          6. Pregnant or breastfeeding women&#xD;
&#xD;
          7. Known allergies or contraindications with regard to substances or procedures of study&#xD;
             therapy&#xD;
&#xD;
          8. Severe, non-healing wounds, ulcers or bone fractures&#xD;
&#xD;
          9. Participation in another clinical trial during this study or within 4 weeks prior to&#xD;
             randomization (Exception: participation in a surgical trial prior to this study, for&#xD;
             instance RECOPANC trial, comparing two different surgical procedures of pancreas&#xD;
             resection)&#xD;
&#xD;
         10. Past or current abuse of illegal or legal drugs or alcohol&#xD;
&#xD;
         11. Other primary malignant diseases in the medical history during the last 5 years&#xD;
             (exceptions: carcinoma in situ of the cervix or adequately treated basal cell&#xD;
             carcinoma of the skin).&#xD;
&#xD;
         12. Permanent cardiac pacemaker&#xD;
&#xD;
         13. Clinically significant cardiovascular or vascular disease or disorder ≤ 6 months&#xD;
             before study enrolment (e.g. myocardial infarction, unstable angina pectoris, chronic&#xD;
             heart failure NYHA ≥ grade 2, uncontrolled arrhythmia, cerebral infarction&#xD;
&#xD;
         14. Gross adiposity defined as BMI &gt; 40 kg/m²&#xD;
&#xD;
         15. Treatment with regional hyperthermia not possible for technical reasons (e.g. metal&#xD;
             implant)&#xD;
&#xD;
         16. &quot;Known documented dihydropyrimidine dehydrogenase (DPD) deficiency&quot;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rolf D. Issels, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum Grosshadern, Medical Center, University of Munich, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rolf D. Issels, MD, PhD</last_name>
    <phone>+49-89-4400-77776</phone>
    <email>heat@med.uni-muenchen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Klinikum Grosshadern, Medical Center, University of Munich</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rolf D. Issels, MD, PhD</last_name>
      <phone>+49-89-4400-77776</phone>
      <email>heat@med.uni-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Rolf D. Issels, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.pankreaszentrum-muenchen.de</url>
    <description>Pankreaszentrum München</description>
  </link>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>February 25, 2010</study_first_submitted>
  <study_first_submitted_qc>February 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2010</study_first_posted>
  <last_update_submitted>November 14, 2017</last_update_submitted>
  <last_update_submitted_qc>November 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Klinikum der Universitaet Muenchen, Grosshadern</investigator_affiliation>
    <investigator_full_name>Rolf D. Issels</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>pancreatic cancer</keyword>
  <keyword>adjuvant treatment</keyword>
  <keyword>hyperthermia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperthermia</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

